Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.

Subcutaneous immunoglobulin (SCIg) therapy is indicated in primary and secondary immunodeficiency diseases. Its use in practice is being extended to autoimmune diseases. Few studies investigated the feasibility and safety of SCIg in these rare conditions.

Corrigendum to "high-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis".

[This corrects the article DOI: 10.1155/2014/458231.].

High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis.

Polymyositis is a rare debilitating condition characterized by chronic inflammation and muscle weakness. Standard treatments include corticosteroids and immunosuppressants; however, resistance to these regimens may develop. Intravenous immunoglobulins (IVIg) are thus recommended for patients with drug-resistant polymyositis.